Advertisement

Low bleeding and thromboembolic risk with continued dabigatran during cardiovascular interventions: the GLORIA-AF study

      Highlights

      • This is the largest study of dabigatran use during cardiovascular interventions in clinical practice from prospectively collected data.
      • Two thirds of the interventions were performed with uninterrupted dabigatran therapy, of which the majority included AF-cardioversions.
      • Continuation of dabigatran therapy during cardiovascular interventions was associated with low risk of major bleeding and stroke/systemic embolism.

      Abstract

      Background

      Prospective data on nonvitamin-K-antagonist oral anticoagulant (NOAC) management during cardiovascular interventions are limited. We therefore evaluated the safety and effectiveness of uninterrupted dabigatran therapy as well as dabigatran management during atrial fibrillation (AF)-cardioversions, AF-ablations, pacemaker implantations and coronary angiography and/or stenting procedures.

      Method

      GLORIA-AF is an international registry programme involving patients with newly diagnosed AF. Dabigatran users were followed for ≤2 years. The primary outcome was occurrence of stroke/systemic embolism and major bleeding ≤8 weeks after a cardiovascular intervention during uninterrupted dabigatran therapy.

      Results

      During the 2-year follow-up, 599 cardiovascular interventions were identified in 479 eligible patients. 412/599 (69%) interventions were performed with uninterrupted dabigatran therapy: 299/354 (84%) AF-cardioversions, 38/89 (43%) AF-ablations, 25/58 (43%) pacemaker implantations, and 50/98 (51%) coronary angiography and/or stenting procedures. During an average follow-up of 8.4 weeks after intervention, one major bleed and one systemic embolic event occurred (risk 0.25% for both outcomes; 95% confidence interval, 0.01%-1.36%).

      Conclusions

      More than two thirds of the interventions were performed with uninterrupted dabigatran therapy, of which most were AF-cardioversions. Uninterrupted dabigatran therapy was associated with low major bleeding and stroke/systemic embolism risk, supporting the favourable safety and effectiveness profile of dabigatran in clinical practice-based settings.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hindricks G
        • Potpara T
        • Dagres N
        • Arbelo E
        • Bax JJ
        • Blomstrom-Lundqvist C
        • et al.
        2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS).
        Eur Heart J. 2020; (;42:373-498)
        • January CT
        • Wann LS
        • Calkins H
        • Chen LY
        • Cigarroa JE
        • Cleveland Jr., JC
        • et al.
        2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons.
        Circulation. 2019; 140 (e125-e51)
        • Airaksinen KE
        • Gronberg T
        • Nuotio I
        • Nikkinen M
        • Ylitalo A
        • Biancari F
        • et al.
        Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study.
        J Am Coll Cardiol. 2013; 62: 1187-1192
        • Hansen ML
        • Jepsen RMHG
        • Olesen JB
        • Ruwald MH
        • Karasoy D
        • Gislason GH
        • et al.
        Thromboembolic risk in 16 274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy.
        Europace. 2015; 17: 18-23
        • Kotecha D
        • Pollack Jr., CV
        • De Caterina R
        • Renda G
        • Kirchhof Jr., P
        Direct oral anticoagulants halve thromboembolic events after cardioversion of AF compared with warfarin.
        J Am Coll Cardiol. 2018; 72: 1984-1986
        • Calkins H
        • Willems S
        • Gerstenfeld EP
        • Verma A
        • Schilling R
        • Hohnloser SH
        • et al.
        Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation.
        N Engl J Med. 2017; 376: 1627-1636
        • Cappato R
        • Marchlinski FE
        • Hohnloser SH
        • Naccarelli GV
        • Xiang J
        • Wilber DJ
        • et al.
        Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation.
        Eur Heart J. 2015; 36: 1805-1811
        • Hohnloser SH
        • Camm J
        • Cappato R
        • Diener HC
        • Heidbuchel H
        • Mont L
        • et al.
        Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial.
        Eur Heart J. 2019; 40: 3013-3021
        • Kirchhof P
        • Haeusler KG
        • Blank B
        • De Bono J
        • Callans D
        • Elvan A
        • et al.
        Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation.
        Eur Heart J. 2018; 39: 2942-2955
        • Doherty JU
        • Gluckman TJ
        • Hucker WJ
        • Januzzi Jr., JL
        • Ortel TL
        • Saxonhouse SJ
        • et al.
        2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: a report of the American College of Cardiology clinical expert Consensus Document Task Force.
        J Am Coll Cardiol. 2017; 69: 871-898
        • Steffel J
        • Verhamme P
        • Potpara TS
        • Albaladejo P
        • Antz M
        • Desteghe L
        • et al.
        The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
        Eur Heart J. 2018; 39: 1330-1393
        • Birnie DH
        • Healey JS
        • Wells GA
        • Ayala-Paredes F
        • Coutu B
        • Sumner GL
        • et al.
        Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2).
        Eur Heart J. 2018; 39: 3973-3979
        • Amsterdam EA
        • Wenger NK
        • Brindis RG
        • Casey Jr., DE
        • Ganiats TG
        • Holmes Jr., DR
        • et al.
        2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines..
        J Am Coll Cardiol. 2014; 64: e139-e228
        • Collet JP
        • Thiele H
        • Barbato E
        • Barthelemy O
        • Bauersachs J
        • Bhatt DL
        • et al.
        2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.
        Eur Heart J. 2020; (Online ahead of print);1;42:1289-1367
        • Knuuti J
        • Wijns W
        • Saraste A
        • Capodanno D
        • Barbato E
        • Funck-Brentano C
        • et al.
        2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes.
        Eur Heart J. 2020; 41: 407-477
        • Vranckx P
        • Leebeek FWG
        • Tijssen JGP
        • Koolen J
        • Stammen F
        • Herman JPR
        • et al.
        Peri-procedural use of rivaroxaban in elective percutaneous coronary intervention to treat stable coronary artery disease The X-PLORER trial.
        Thromb Haemostasis. 2015; 114: 258-267
        • Vranckx P
        • Verheugt FW
        • de Maat MP
        • Ulmans VA
        • Regar E
        • Smits P
        • et al.
        A randomised study of dabigatran in elective percutaneous coronary intervention in stable coronary artery disease patients.
        EuroIntervention. 2013; 8: 1052-1060
        • Huisman MV
        • Lip GY
        • Diener HC
        • Dubner SJ
        • Halperin JL
        • Ma CS
        • et al.
        Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation.
        Am Heart J. 2014; 167: 329-334
        • Huisman MV
        • Rothman KJ
        • Paquette M
        • Teutsch C
        • Diener HC
        • Dubner SJ
        • et al.
        Antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation: the GLORIA-AF Registry, phase II.
        Am J Med. 2015; 128 (e1): 1306-1313
        • Schulman S
        • Kearon C
        Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.
        J Thromb Haemost. 2005; 3: 692-694
        • Douketis JD
        • Spyropoulos AC
        • Kaatz S
        • Becker RC
        • Caprini JA
        • Dunn AS
        • et al.
        Perioperative bridging anticoagulation in patients with atrial fibrillation.
        N Engl J Med. 2015; 373: 823-833
        • January CT
        • Wann LS
        • Alpert JS
        • Calkins H
        • Cigarroa JE
        • Cleveland Jr., JC
        • et al.
        2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.
        J Am Coll Cardiol. 2014; 64: e1-76
        • Camm AJ
        • Lip GY
        • De Caterina R
        • Savelieva I
        • Atar D
        • Hohnloser SH
        • et al.
        2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association.
        Eur Heart J. 2012; 33: 2719-2747
        • Kottmaier M
        • Bourier F
        • Pausch H
        • Reents T
        • Semmler V
        • Telishevska M
        • et al.
        Safety of uninterrupted periprocedural edoxaban versus phenprocoumon for patients who underwent left atrial catheter ablation procedures.
        Am J Cardiol. 2018; 121: 445-449
        • Ukaigwe A
        • Shrestha P
        • Karmacharya P
        • Hussain SK
        • Samii S
        • Gonzalez MD
        • et al.
        Meta-analysis of efficacy and safety of apixaban and uninterrupted apixaban therapy compared to vitamin K antagonists in patients undergoing catheter ablation for atrial fibrillation.
        J Interv Card Electrophysiol. 2017; 48: 223-233
        • Rowley CP
        • Bernard ML
        • Brabham WW
        • Netzler PC
        • Sidney DS
        • Cuoco F
        • et al.
        Safety of continuous anticoagulation with dabigatran during implantation of cardiac rhythm devices.
        Am J Cardiol. 2013; 111: 1165-1168
        • Jennings JM
        • Robichaux R
        • McElderry HT
        • Plumb VJ
        • Gunter A
        • Doppalapudi H
        • et al.
        Cardiovascular implantable electronic device implantation with uninterrupted dabigatran: comparison to uninterrupted warfarin.
        J Cardiovasc Electrophysiol. 2013; 24: 1125-1129
        • January CT
        • Wann LS
        • Alpert JS
        • Calkins H
        • Cigarroa JE
        • Cleveland Jr., JC
        • et al.
        2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.
        Circulation. 2014; 130: 2071-2104
        • Steffel J
        • Verhamme P
        • Potpara TS
        • Albaladejo P
        • Antz M
        • Desteghe L
        • et al.
        The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
        Eur Heart J. 2018; 39: 1330-1393